Trinity Delta’s business is institutional quality issuer-paid equity research.

Our company coverage and past research notes can be accessed via the dedicated Company Pages below, or from our Research Library.

Avacta
Avacta is a clinical stage biotech focused on the novel pre|CISION platform to generate peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment.
Read more
HUTCHMED
HUTCHMED, a Hong Kong-based biopharmaceutical company, developing and commercialising innovative, highly selective oral therapies for oncology indications.
Read more
Oxford BioDynamics
Oxford BioDynamics develops 3D genomic diagnostics using its proprietary EpiSwitch technology platform. Two tests, EpiSwitch CiRT (immuno-oncology response) and EpiSwitch PSE (prostate cancer) are being rolled out commercially.
Read more
Scancell
Scancell is a clinical-stage immuno-oncology specialist. The key value drivers are iSCIB1+, the lead ImmunoBody programme, and Modi-1, the lead Moditope programme. The novel GlyMab glycan antibodies are earlier in development.
Read more

Subscribe to our research

Please sign up here to be added to our distribution database. 

    © 2019-2026 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).